Researchers at AAIC presented several imaging measures that may help explain the phenomenon of preserved cognition in the face of AD pathology.
Researchers at AAIC reinforced the idea that tau pathology drives cognitive decline, although amyloid plaques were implicated in semantic memory deficits.
Researchers at AAIC described different correlates of CSF and PET measures of Aβ and tau.
The aging brain winds down rapid glucose metabolism in regions that will go on to accumulate amyloid, perhaps raising the risk of neurodegeneration.
Interim data from IDEAS study find that amyloid PET has a greater effect in real-world practice than in research settings. Nearly half of people diagnosed with AD did not have the disease.
At AAIC, researchers debuted a method that detects changes in plasma Aβ42 in people with brain amyloid. If confirmed, a widely available screening test for presymptomatic AD could follow.
Gaps surrounding blood vessels in the brain may predict cognitive decline and vascular dementia.
Analysis of brain tissue from Alzheimer’s patients offers a glimpse of proteomic changes in the disease.
New diagnostic guidelines on dementia with Lewy bodies fold in science about sleep and the heart, two aspects that distinguish this disorder from Alzheimer’s and Parkinson’s.
Longitudinal ADNI data revealed that people with elevated Aβ declined toward AD, while those with normal levels maintained their cognitive abilities.
People with ALS—especially those who progress fast—express myriad inflammatory genes in their blood monocytes.
In the field’s march toward automated testing, scientists for the first time used biomarker cutoffs determined in one cohort to predict amyloid accumulation in a second. It worked.
Emerging data on new tau ligands raise hope of more signal, less noise, and help with a broad range of tauopathies. Read news culled from the AD/PD and HAI 2017 meetings.
Unlikely a disease marker, poly glycine-proline might track therapeutic efficacy in clinical trials.
The largest study yet on neurofilament light chain suggests plasma levels rise with disease and correlate with other signs of neurodegeneration.